Superstring Capital Management »

Inozyme Pharma shares owned by Superstring Capital Management

Quarter-by-quarter ownership of Inozyme Pharma (INZY) shares owned by Superstring Capital Management from 13F filings

Historical chart of Superstring Capital Management investment in Inozyme Pharma

Tip: Access up to 7 years of quarterly data

All positions including Inozyme Pharma held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inozyme Pharma by Superstring Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $528k 124k 4.26

More positions owned by Superstring Capital Management

ImmunoGen
Cytokinetics Com New (CYTK)
89bio (ETNB)
Ionis Pharmaceuticals (IONS)
Ideaya Biosciences (IDYA)
Protagonist Therapeutics (PTGX)
Immunovant (IMVT)
Bridgebio Pharma (BBIO)
Day One Biopharmaceuticals I (DAWN)
Marinus Pharmaceuticals Com New (MRNS)
Neurocrine Biosciences (NBIX)
Urogen Pharma (URGN)
Savara (SVRA)
Roivant Sciences SHS (ROIV)
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH)

View all positions for Superstring Capital Management

Top funds holding Inozyme Pharma

Samlyn Capital
Eventide Asset Management
NEA Management Company
Vanguard Group
Sphera Funds Management
Samsara BioCapital
Blue Owl Capital Holdings
Millennium Management
Laurion Capital Management
Octagon Capital Advisors
Goldman Sachs Group
Kennedy Capital Management
Overbrook Management Corp.
Citadel Advisors
GSA Capital Partners

View all funds holding Inozyme Pharma